Additionally, pioglitazone—a PPARγ agonist approved for diabetes—has demonstrated the ability to reduce tumor size and prevent metastasis in animal models of PAX8/PPARγ fusion-positive FTC, with preliminary clinical evidence supporting its use [NCT01655719] [38]. This evidence concerns the gene PAX8 and diabetes mellitus.